Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C107672-10mg | 10mg | In stock | $86.90 | |
C107672-50mg | 50mg | In stock | $151.90 |
Anti-inflammatory and antiproliferative agent
Synonyms | celastrol | 34157-83-0 | Tripterin | Tripterine | (2R,4aS,6aS,12bR,14aS,14bR)-10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylic acid | NSC70931 | (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9, |
---|---|
Specifications & Purity | 98% |
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Product Description | Celastrol, Celastrus scandens, a compound originally purified from Tripterygium wilfordii, has been shown to be an anti-peroxidative and anti-angiogenic agent. Mechanistic studies suggest that Celastrol suppresses levels of VEGF and Flk-1 receptors, VEGFR-1 and VEGFR-2, which may reduce signal transduction between the two growth factors. Additionally, Celastrol has demonstrated the ability to disrupt critical interaction of Glu33 (Hsp90) and Arg167 (Cdc37) in the superchaperone complex which causes anti-proliferative activity in vitro and inhibit Topo II (topoisomerase II) activity in vitro (IC50 = 7.41 μM). Celastrol, Celastrus scandens is an inhibitor of Hsp90. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (2R,4aS,6aR,6aS,14aS,14bR)-10-hydroxy-2,4a,6a,6a,9,14a-hexamethyl-11-oxo-1,3,4,5,6,13,14,14b-octahydropicene-2-carboxylic acid |
---|---|
INCHI | InChI=1S/C29H38O4/c1-17-18-7-8-21-27(4,19(18)15-20(30)23(17)31)12-14-29(6)22-16-26(3,24(32)33)10-9-25(22,2)11-13-28(21,29)5/h7-8,15,22,31H,9-14,16H2,1-6H3,(H,32,33)/t22-,25-,26-,27+,28-,29+/m1/s1 |
InChi Key | KQJSQWZMSAGSHN-JJWQIEBTSA-N |
Canonical SMILES | CC1=C(C(=O)C=C2C1=CC=C3C2(CCC4(C3(CCC5(C4CC(CC5)(C)C(=O)O)C)C)C)C)O |
Isomeric SMILES | CC1=C(C(=O)C=C2C1=CC=C3[C@]2(CC[C@@]4([C@@]3(CC[C@@]5([C@H]4C[C@](CC5)(C)C(=O)O)C)C)C)C)O |
WGK Germany | 2 |
Alternate CAS | 34157-83-0 |
PubChem CID | 122724 |
NSC Number | 70931 |
UN Number | 2811 |
MeSH Entry Terms | 3-hydroxy-24-nor-2-oxo-1(10),3,5,7-friedelatetraen-29-oic acid;celastrol;tripterin;tripterine |
Molecular Weight | 450.61 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
G2403051 | Certificate of Analysis | Jul 29, 2022 | C107672 |
K2222433 | Certificate of Analysis | Jul 29, 2022 | C107672 |
K2222543 | Certificate of Analysis | Jul 29, 2022 | C107672 |
C2218429 | Certificate of Analysis | Feb 22, 2022 | C107672 |
C2218454 | Certificate of Analysis | Feb 22, 2022 | C107672 |
B2212050 | Certificate of Analysis | Feb 17, 2022 | C107672 |
Solubility | Soluble in DMSO (>10 mg/ml), ethanol, DMF:PBS(pH 7.2)(1:10), and DMF. Insoluble in water. |
---|---|
Sensitivity | Heat sensitive |
Specific Rotation[α] | -122.7° (C=0.1,CHCl3) |
Melt Point(°C) | 203°C(lit.) |
Pictogram(s) | GHS06 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed |
Precautionary Statements | P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P316:IF SWALLOWED: Get emergency medical help immediately. |
WGK Germany | 2 |
Starting at $259.90
Starting at $130.90
1. Ping Sheng, Chao Bu, Tanyue Hui, Lili Zhou, Hao Chen, Guoliang Zhou. (2023) Polydopamine-activated celastrol carbon dots for synergistic chemotherapy-photothermal therapy of tumors. International Journal of Pharmaceutics-X, 6 (7): (100218). [PMID:38033396] |
2. Jiwen Fan, Meng Ren, Weiwei Chen, Haodong Wang, Yuquan He. (2023) Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats. INTERNATIONAL IMMUNOPHARMACOLOGY, 121 (110511). [PMID:37343368] |
3. Xiaoli Li, Guangbei Zhu, Xintong Yao, Ning Wang, Ronghui Hu, Qingxin Kong, Duanfang Zhou, Liangyuan Long, Jiali Cai, Weiying Zhou. (2022) Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells. OncoTargets and Therapy, [PMID:30588010] |
4. Qiang Chen, Chunjing Guo, Zhongxin Liu, Min Cao, Wenxin Wang, Dandan Zhang, Hongxu Geng, Ningning Diao, Daquan Chen. (2023) Multifunctional nanoparticles with anti-inflammatory effect for improving metabolic syndromes. JOURNAL OF DRUG TARGETING, 31 (3): (286-295). [PMID:36315421] |
5. Bo Yu, Yiping Shen, Xuejie Zhang, Lijuan Ding, Zheng Meng, Xiaotong Wang, Meihua Han, Yifei Guo, Xiangtao Wang. (2022) Poly(methacrylate citric acid) as a Dual Functional Carrier for Tumor Therapy. Pharmaceutics, 14 (9): (1765). [PMID:36145512] |
6. Yunpeng Qi,Renping Wang,Liang Zhao,Lei Lv,Fan Zhou,Tian Zhang,Feng Lu,Hongli Yan,Gengli Duan. (2018-08-03) Celastrol Suppresses Tryptophan Catabolism in Human Colon Cancer Cells as Revealed by Metabolic Profiling and Targeted Metabolite Analysis.. Biological & pharmaceutical bulletin, 41 ((8)): (1243-1250). [PMID:30068874] |
1. Ping Sheng, Chao Bu, Tanyue Hui, Lili Zhou, Hao Chen, Guoliang Zhou. (2023) Polydopamine-activated celastrol carbon dots for synergistic chemotherapy-photothermal therapy of tumors. International Journal of Pharmaceutics-X, 6 (7): (100218). [PMID:38033396] |
2. Jiwen Fan, Meng Ren, Weiwei Chen, Haodong Wang, Yuquan He. (2023) Celastrol relieves myocardial infarction-induced cardiac fibrosis by inhibiting NLRP3 inflammasomes in rats. INTERNATIONAL IMMUNOPHARMACOLOGY, 121 (110511). [PMID:37343368] |
3. Xiaoli Li, Guangbei Zhu, Xintong Yao, Ning Wang, Ronghui Hu, Qingxin Kong, Duanfang Zhou, Liangyuan Long, Jiali Cai, Weiying Zhou. (2022) Celastrol induces ubiquitin-dependent degradation of mTOR in breast cancer cells. OncoTargets and Therapy, [PMID:30588010] |
4. Qiang Chen, Chunjing Guo, Zhongxin Liu, Min Cao, Wenxin Wang, Dandan Zhang, Hongxu Geng, Ningning Diao, Daquan Chen. (2023) Multifunctional nanoparticles with anti-inflammatory effect for improving metabolic syndromes. JOURNAL OF DRUG TARGETING, 31 (3): (286-295). [PMID:36315421] |
5. Bo Yu, Yiping Shen, Xuejie Zhang, Lijuan Ding, Zheng Meng, Xiaotong Wang, Meihua Han, Yifei Guo, Xiangtao Wang. (2022) Poly(methacrylate citric acid) as a Dual Functional Carrier for Tumor Therapy. Pharmaceutics, 14 (9): (1765). [PMID:36145512] |
6. Yunpeng Qi,Renping Wang,Liang Zhao,Lei Lv,Fan Zhou,Tian Zhang,Feng Lu,Hongli Yan,Gengli Duan. (2018-08-03) Celastrol Suppresses Tryptophan Catabolism in Human Colon Cancer Cells as Revealed by Metabolic Profiling and Targeted Metabolite Analysis.. Biological & pharmaceutical bulletin, 41 ((8)): (1243-1250). [PMID:30068874] |